Repeat renal biopsy in lupus nephritis – unnecessary harm and risk of complications or important diagnostic tool with clinical consequences?

por Haładyj, Ewa, Cervera, Ricard
Publicado 2016

Do we still need renal biopsy in lupus nephritis?

por Haładyj, Ewa, Cervera, Ricard
Publicado 2016

Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases

por Haładyj, Ewa, Olesińska, Marzena
Publicado 2016

Antimalarials – are they effective and safe in rheumatic diseases?

por Haładyj, Ewa, Sikora, Mariusz, Felis-Giemza, Anna, Olesińska, Marzena
Publicado 2018

Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome

por Haładyj, Ewa, Paradowska-Gorycka, Agnieszka, Felis-Giemza, Anna, Olesińska, Marzena
Publicado 2016

Relationship between type of skin lesions and nailfold capillaroscopy pattern in mixed connective tissue disease

por Felis-Giemza, Anna, Ornowska, Sylwia, Haładyj, Ewa, Czuszyńska, Zenobia, Olesińska, Marzena
Publicado 2021

Treatment of rheumatic diseases and hepatitis B virus coinfection

por Felis-Giemza, Anna, Olesińska, Marzena, Świerkocka, Katarzyna, Więsik-Szewczyk, Ewa, Haładyj, Ewa
Publicado 2014

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis

por Lopez-Romero, Pedro, de la Torre, Inmaculada, Haladyj, Ewa, Aletaha, Daniel, Smolen, Josef S
Publicado 2022

A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus

por Dörner, Thomas, Vital, Edward M., Ohrndorf, Sarah, Alten, Rieke, Bello, Natalia, Haladyj, Ewa, Burmester, Gerd
Publicado 2022

RORC2 Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis

por Paradowska-Gorycka, Agnieszka, Stypinska, Barbara, Pawlik, Andrzej, Romanowska-Prochnicka, Katarzyna, Haladyj, Ewa, Manczak, Malgorzata, Olesinska, Marzena
Publicado 2016

Relative Impact of Pain and Disease Activity on Improvements in Fatigue: Results From 2 Baricitinib Phase 3 Clinical Trials

por Fautrel, Bruno, Wu, Jianmin, Wang, Duzhe, Haladyj, Ewa, van de Laar, Mart A. F. J., Takeuchi, Tsutomu
Publicado 2023

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis

por Hernández-Cruz, Blanca, Kiltz, Uta, Avouac, Jérôme, Treuer, Tamas, Haladyj, Ewa, Gerwien, Jens, Gupta, Chandreyee Dutta, Conti, Fabrizio
Publicado 2023

Relationship between VEGF Gene Polymorphisms and Serum VEGF Protein Levels in Patients with Rheumatoid Arthritis

por Paradowska-Gorycka, Agnieszka, Pawlik, Andrzej, Romanowska-Prochnicka, Katarzyna, Haladyj, Ewa, Malinowski, Damian, Stypinska, Barbara, Manczak, Malgorzata, Olesinska, Marzena
Publicado 2016

FLT-1 gene polymorphisms and protein expression profile in rheumatoid arthritis

por Paradowska-Gorycka, Agnieszka, Sowinska, Anna, Pawlik, Andrzej, Malinowski, Damian, Stypinska, Barbara, Haladyj, Ewa, Romanowska-Prochnicka, Katarzyna, Olesinska, Marzena
Publicado 2017

Comparative Effectiveness of First‐Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set

por Ciciriello, Sabina, Littlejohn, Geoffrey, Treuer, Tamas, Gibson, Kathryn A., Haladyj, Ewa, Youssef, Peter, Bird, Paul, O'Sullivan, Catherine, Smith, Tegan, Deakin, Claire T.
Publicado 2023

Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

por Bieber, Thomas, Feist, Eugen, Irvine, Alan D., Harigai, Masayoshi, Haladyj, Ewa, Ball, Susan, Deberdt, Walter, Issa, Maher, Grond, Susanne, Taylor, Peter C.
Publicado 2023

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

por Bieber, Thomas, Feist, Eugen, Irvine, Alan D., Harigai, Masayoshi, Haladyj, Ewa, Ball, Susan, Deberdt, Walter, Issa, Maher, Grond, Susanne, Taylor, Peter C.
Publicado 2022

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

por Taylor, Peter C., Laedermann, Cedric, Alten, Rieke, Feist, Eugen, Choy, Ernest, Haladyj, Ewa, De La Torre, Inmaculada, Richette, Pascal, Finckh, Axel, Tanaka, Yoshiya
Publicado 2023

IL-35, TNF-α, BAFF, and VEGF serum levels in patients with different rheumatic diseases

por Wojdasiewicz, Piotr, Wajda, Anna, Haładyj, Ewa, Romanowska-Próchnicka, Katarzyna, Felis-Giemza, Anna, Nałęcz-Janik, Jolanta, Walczyk, Marcela, Olesińska, Marzena, Tarnacka, Beata, Paradowska-Gorycka, Agnieszka
Publicado 2019

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

por Taylor, Peter C., Bieber, Thomas, Alten, Rieke, Witte, Torsten, Galloway, James, Deberdt, Walter, Issa, Maher, Haladyj, Ewa, De La Torre, Inmaculada, Grond, Susanne, Wollenberg, Andreas
Publicado 2023